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BACKGROUND. About 43% of men with low Gleason grade prostate cancer (PCa) at
biopsy will be finally diagnosed with high-grade PCa at radical prostatectomy (RP). Gleason
sum at RP is a good indicator of biochemical recurrence and poor clinical outcome. Therefore,
there is a need to improve clinical evaluation of PCa aggressiveness in order to choice appro-
priate treatment. To this aim an easy-available tool is represented by circulating biomarkers.
Among these, the best candidates are some molecules involved in PCa pathogenesis such as
IGFBP-2 and IGFBP-3, IL-6, and its soluble receptor (SIL-6R).
METHODS. In this study, we evaluated the ability of preoperative IGFBP-2, IGFBP-3, IL-6,
and SIL-6R serum levels to predict Gleason score upgrade in 52 PCa patients.
RESULTS. We found that IGFBP-3 median levels were significantly lower in patients who
showed Gleason upgrading from biopsy to RP (P ¼ 0.024). We also found an association
between biopsy T-stage and Gleason Upgrade (P ¼ 0.011). Using multivariate logistic
regression model, we demonstrated that the association of IGFBP-3 serum levels together
with biopsy T-stage and biopsy Gleason score was useful to calculate a prognostic risk score.
ROC curve analysis of risk score showed a good ability to predict GSU (AUC ¼ 0.81; 95% CI
0.69–0.93).
CONCLUSIONS. Our results suggest that preoperative IGFBP-3 circulating levels determi-
nation may be useful to predict Gleason score upgrading alone and/or in combination with
biopsy T-stage and biopsy Gleason score. Prostate 72: 100–107, 2012.
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INTRODUCTION
Prostate cancer (PCa) is the prevalent malignant
disease in men in most Western countries [1]. Biopsy
Gleason score together with stage, serum prostate-
specific antigen (PSA) and tumor volume is used to
carefully select men with low-risk PCa that will likely
benefit from treatment other than radical prostatec-
tomy (RP) such as active surveillance (AS) or low
dose brachytherapy (LD-BT) [2,3]. Many efforts have
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been made in order to maximize cancer detection at
initial diagnosis and to increase the concordance of
Gleason scores of needle biopsies and prostatectomy
specimens especially improving biopsy techniques
[4–6]. Unfortunately, many men (about 43%) with
low-grade PCa at biopsy will be finally diagnosed
with high-grade PCa at RP. Therefore, RP Gleason
score is better than biopsy Gleason score as indicator
of biochemical recurrence and poor clinical outcome
[7–10], advising that Gleason sum upgrading (GSU)
could be clinically relevant to estimate the probability
of a more aggressive variant of PCa [11]. At present,
to predict Gleason sum the model includes clinical
stage, biopsy Gleason, and serum PSA [12]. However,
the relationship between PSA and tumor grade is not
clear because tissue PSA concentration decrease with
increasing Gleason sum [13]. Free PSA (F-PSA) testing
as an adjunct to total PSA has improved the diagnos-
tic performance in men with total PSA levels of 4–
10 ng/ml, but data on the usefulness of percentage of
F-PSA as predictor of aggressive disease progression
are inconclusive [14,15]. Several alternative bio-
markers have been proposed to supplement or
replace PSA in order to predict the natural behavior
of the tumor [16–19]. The candidate biomarkers are
molecules involved in biological pathways thought to
be important in pathogenesis and progression of
PCa and potentially able to refine clinical decision
making. These markers include insulin-like growth
factor-binding protein-2 (IGFBP-2) and -3 (IGFBP-3),
interleukin-6 (IL-6), and its soluble receptor (sIL-6R).
Insulin-like growth factors (IGFs) have mitogenic
effects on epithelial cells [20] and are protected from
degradation by their own binding protein; moreover,
IGFBPs transport IGFs to distant effector sites and
modulate the interaction with the surface receptors,
affecting the cellular response [21]. Several studies
showed the association of local expression of IGFs,
IGFBP-2, and IGFBP-3 with tumor grade and patho-
logic stage in breast, lung, colon, and PCa [22–25]. IL-
6, a cytokine involved in immunological and inflam-
matory response, has been shown to have a role in
proliferative and invasive potential of cancer cell
[26,27], increasing angiogenesis, invasion [28,29], and
promoting immune escape by tumor cells [30]. The
soluble form of IL-6 trans-membrane receptor (sIL-
6R) is able to bind the cytokine and potentiate the sig-
nal transduced or activate it in cells that do not
express the receptor [31]. This kind of signal transduc-
tion, called IL-6 trans-signaling (IL-6TS) has a major
relevance in the pathogenesis of chronic inflamma-
tory and malignant disease [32–34]. In this study, we
used a database prospectively collected during a short
period to evaluate if the preoperative serum levels of
IL-6, sIL-6R, IGFBP-2, and IGFBP-3 may be used to
predict GSU. These parameters may be useful when
consulting patients before treatment decision are
made.
MATERIALSANDMETHODS
Patients
During a 1-year period, a total of 52 subjects with
PCa, age ranging from 51 to 75 (median ¼ 64 years),
were enrolled at our institution. Inclusion criteria
were no evidence of active infection or inflammatory
disease, no neo-adjuvant androgen therapy, PSA <
20 ng/ml, clinical stage <IIc. Patients were classified
by clinical stage, pathologic Gleason sum, and signifi-
cant GSU. Significant GSU is defined as a Gleason
sum increase between biopsy and RP either from 6
to 7 or from 7 to 8 [35]. Clinical stage was assigned
by the attending urologist according to the 2002 TNM
system. Between 14 and 16 needle biopsy cores were
obtained under transrectal-ultrasound (TRUS) guid-
ance: 40 (74%) had 14 cores taken and 15 (27%) had 16
cores taken. Primary and secondary Gleason score
were assigned by the same pathology. All prostatec-
tomy specimens were processed according to the
Stanford protocol and were also graded according to
the Gleason system.
MeasurementofBiomarkersinSerum
Preoperative serum samples were collected before
digital rectal examination (DRE) and TRUS. Blood
was collected into non-heparinized tubes and serum
was separated within 1 h of blood collection. The
serum was stored at 808C and then thawed just
prior to testing. Serum levels of PSA, F-PSA, IL-6, and
IGFBP-3 were measured using the Immulite 2000
automated assay (DPC, Los Angeles, CA). Concen-
tration of sIL-6R (R&D Systems, Minneapolis, MN)
and IGFBP-2 (DSL, Webster, TX) in serum was deter-
mined according to the manufacturer’s instructions
using ELISA test. Every sample was run in duplicate
and the mean was used. The differences between the
two measurements were minimal.
DataAnalysis andStatistics
All statistical analyses were performed using the R
statistical computing environment (vers. 2.12.1). Data
for continuous variables are summarized as median
with IQ range. Data for categorical variables are pre-
sented as frequencies and percentages. Univariate
analysis for quantitative variables was based on the
non-parametric Mann–Whitney U-test. Chi square
test or Fisher exact test was used in case of qualitative
variables.
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To build a prognostic score able to predict a signifi-
cant GSU, a multivariate logistic regression modeling
was applied using a backward elimination strategy
for variable selection. The full model included the
preoperative serum levels of PSA, F-PSA, F/T PSA
ratio, IL-6, sIL-6R, IGFBP-2, IGFBP-3 together with the
clinical stage (dichotomized as T1 or T2) and the
biopsy Gleason score (dichotomized as 5, 6). At
each step, the variable with the highest P-values
associated with the decrease in 2 log(likelihood)
was removed until only effects significantly differing
from 0 with P < 0.05 were left in the model. The lin-
ear predictor of the resulting final model was used as
the prognostic risk score.
The performance of the estimated linear predictor
was evaluated by computing the area under the
receiver operating characteristic (ROC) curve (AUC).
Confidence intervals for the AUC and for sensitivities
and specificities values were obtained using boot-
strapping [36]. Calibration of the fitted model was
measured with the Hosmer–Lemeshow statistic [37].
Due to the lack of a test data set, the validity of the
prediction model was assessed by a bootstrapping
procedure as described in [38] to correct the AUC for
over-optimism which occurs when the fit of a model
is evaluated using the same data in which the
model was built. Two hundred bootstrap samples
were drawn with replacement and with the same
size as the original sample. The logistic regression
model was fitted in the bootstrap sample and the
generated scoring system was evaluated, in terms
of the AUC metric, in both the bootstrap sample
(training set) and in the original sample (test set).
The difference between the two AUC, averaged
over the 200 bootstrap samples, furnished a stable
estimate of the optimism that was subtracted from the
apparent performance in order to obtain the opti-
mism-corrected estimate.
In all the analysis, a P < 0.05 was considered to be
statistically significant.
RESULTS
Table I lists the clinical and pathological character-
istics of patients stratified by clinical stage, PSA, %
F-PSA, biopsy Gleason score and RP Gleason score.
Significant GSU was observed in 19 patients
(36.5%): 14 from 6 to 7 and 5 from 7 to 8. The rate
of GSU between biopsy and RP in our study popu-
lation is consistent with several previous reports,
where upgrading was present in 32.0% [39], 29.3%
[12], and 35.5% [40]of the samples. These data may
suggest that our study population is a representative
sample for GSU studies. The transition matrix of Glea-
son score from biopsy to prostatectomy was showed
in Table II. The association between the outcome of a
significant GSU and all the study variables including
the age at serum collection, the serum levels of the
analyzed biomarkers, the biopsy T-stage, and the
biopsy Gleason score was indicated in Table III. In
this univariate analysis, the serum levels of IGFBP3
and T-stage at biopsy were the only variables signifi-
cantly associated to the presence of GSU. This associ-
ation was confirmed in the multivariate logistic
regression model where also the Gleason score at
biopsy emerged as an independent significant predic-
tors of GSU, after adjusting for the other study vari-
ables. The coefficients of the final model together with
their 95% CI are shown in Table IV. This model pro-
duced a risk score able to predict significant GSU. The
receiver operating characteristic (ROC) curve describ-
ing the prognostic performance of the risk score,
showed in Figure 1, indicated a good ability to
identify patients who will harbor a higher grade can-
cer diagnosed at RP [AUC ¼ 0.81 (95% CI 0.69–0.93)].
The optimal cut-off value for the prognostic score
maximizing the sum of sensitivity and specificity was
0.42 (corresponding to an estimated probability of
GSU of 0.4) with a sensitivity of 0.79 (95% CI 0.58–
0.95) and a specificity of 0.82 (95% CI 0.67–0.94). The
Hosmer and Lemeshow statistic was 9.4 (P ¼ 0.309),
TABLE I. ClinicalCharacteristicsof 52Patients
Characteristics Number of patients (%)
Clinical stage
T1a 1 (2)
T1c 22 (42)
T2a 17 (33)
T2b 2 (9)
T2c 10 (18)
PSA (ng/ml)
0–4 28 (54)
4.1–10 19 (36)
10.1–20 5 (9)
% F-PSA
1–10 26 (50)
10.1–15 17 (33)
15.1–20 5 (9)
>20 4 (7)
Biopsy Gleason score
2–4 3 (5)
5–6 32 (63)
7 17 (31)
Prostate specimen Gleason score
5–6 24 (46)
7 21 (40)
8–10 7 (13)
102 Terraccianoet al.
The Prostate
thus showing no evidence for a poor calibration of the
fitted model. According to the bootstrapping pro-
cedure, the optimism in the AUC was small (0.03)
resulting in a optimism-corrected estimate of 0.78
(95% CI 0.67–0.90). The dot-plot of the risk score in all
the patients, classified according to the presence or
the absence of a significant GSU is showed in
Figure 2. The dashed line indicates the optimal cut-off
value as derived from the ROC analysis.
DISCUSSION
PSA-based screening has determined detection
of early-stage disease at a high cost of overdiagnosis
and overtreatment. Consequently, at biopsy there
is a need to adequately distinguish between aggres-
sive tumors that require immediate invasive treat-
ment and ‘‘clinically insignificant’’ tumors [41].
Several tumor-associated prognostic biomarkers with
biological relevance in prostate tumorigenesis or
tumor progression have been proposed [17,18]. IGFs
family members, IL-6 and its soluble receptor have
shown potential as prognostic indicators in PCa
[42,43]. Furthermore, recent studies suggested also
tertiary Gleason component as prognostic tool at
biopsy [44,45]. In this context, we evaluated the risk
for PCa patients in our study population to harbor a
higher grade cancer as well as the ability of the
examined biomarkers to estimate the magnitude of
this risk. We showed that low IGFBP-3 levels are good
predictor of high-grade cancer diagnosed at RP. Our
finding may not be surprising since circulating
IGFBP-3 levels previously have been shown to be
lowest in patients with bony metastases and lower in
patients with metastases to regional lymphnodes than
in patients with non-metastatic PCa or in healthy
TABLE II. TransitionMatrixofGleasonScoreFromBiopsytoRadicalProstatectomy
Gleason Score at biopsy
Gleason Score at Prostatectomy
5 6 7 8 9 Total
4 1 0 2 0 0 3
5 2 1 3 0 0 6
6 1 18 9 0 0 28
7 0 2 8 2 3 15
Total 4 21 22 2 3 52
TABLE III. DescriptiveStatisticsofMeasuredVariablesinSerumofPatientsStratifiedbyGleasonUpgrade
Continous Variables
Patients without GSU (n ¼ 33, 63%) Patients with GSU (n ¼ 19, 37%)
P valueMedian IQR Median IQR
Age 65 61–68 64 61–68 0.956
T-PSA, ng/ml 3.84 0.21–17.9 4.06 1.25–16.4 0.812
F-PSA, ng/ml 0.4 0.06–2.18 0.47 0.07–2.43 0.398
F-PSA/T-PSA, % 0.11 0.04–0.33 0.11 0.05–0.27 0.977
IL-6, pg/ml 6.27 2.30–158 6.82 5.4–281 0.408
sIL-6R, ng/ml 61.26 34.22–133.7 70.86 28.62–149.7 0.119
IGFBP-3, mg/ml 3.48 1.48–5.67 2.51 1.9–4.26 0.024
IGFBP-2, ng/ml 812.5 0–1,800 850 200–1,450 0.924
Categorical Variables
Patients without GSU Patients with GSU
P valueN % N %
Biopsy stage
T1 19 57.58 4 21.05 0.011
T2 14 42.42 15 78.95
Biopsy Gleason Score
5 4 12.12 5 26.32 0.260
6 29 87.88 14 73.68
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subjects [46]. Other authors showed that local expres-
sion of IGFBP-3 has been inversely associated with
Gleason score [25]. These clinical observations agree
with biological role of IGFBPs that bind and sequester
IGF-1 molecules, suppressing growth under physio-
logic circumstances [47]. Proteases in plasma and tis-
sues hydrolyze IGFBPs, releasing IGFs and further
regulating their action [48]. This kind of regulation is
well-rendered in prostate gland, where PSA functions
as an IGFBP-3 protease reversing the inhibitory effect
of the binding protein on prostate cell growth [49].
Furthermore, it has been reported that IGFBP-3 exerts
distinct biological actions such as cell growth inhi-
bition and induction of apoptosis through an IGF/
IGF-1 receptor-independent manner in a variety of
cancer cells [50–52]. Recently, Ingermann et al. [53]
showed IGFBP-3 suppression in breast and PCa. Of
note, in androgen-independent PCa progression,
androgen-receptor (AR) signaling may be enhanced
through activation of AR by growth factors such as
IGF and EGF [54].
Previous investigations provided evidence of the
relationship between biopsy T-stage and RP Gleason
score [7,55]. However, previous authors suggested
that single variables may be of limited utility to pre-
dict biopsy Gleason score upgrading [39,56,57]. We
used logistic regression analysis to evaluate the use of
multivariate model and we calculated a risk score
including serum IGFBP-3, biopsy T-stage, and biopsy
Gleason sum. So, in agree with univariate analysis
which indicated a significant association between
serum IGFBP-3 (but not serum PSA) and GSU, we
combine serum IGFBP-3 in place of serum PSA, as in
the currently used model [12], with biopsy T-stage
and biopsy Gleason sum. Our data hold with protec-
tive role of IGFBP-3 on proliferative potential of
TABLE IV. MultivariateLogisticRegressionModelCoefficients
Variable Adjusted b-coefficient Standard error P value
95% CI
Lower Bound Upper Bound
Biopsy stage
T2 versus T1 1.73 0.76 0.023 0.24 3.22
Biopsy Gleason score
6 versus 5 1.71 0.86 0.048 3.39 0.02
IGFBP-3, mg/ml 0.91 0.46 0.023 1.80 0.02
Constant 2.56 1.38 0.064 0.14 5.26
Fig. 1. ROCcurve showingrisk scoreability topredict significant
GSU.Verticalandhorizontal arrowedlinesrepresent the95%CI for
sensitivityandspecificityassociatedto theoptimalcut-off.
Patients without GSU Patients with GSU
Ri
sk
 s
co
re
Fig. 2. Dot plot showing risk score in all the patients stratified
by significant GSU. The dashed line indicates the optimal cut-off
valueasderivedfromtheROCanalysis.
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cancer cell [48,53] and with not yet clear relationship
between PSA and Gleason score.
In conclusion, we found that IGFBP-3 could
represent an important tool to predict the risk of
patient with biopsy Gleason score 6 to conceal a
higher grade cancer diagnosed at RP. Using a model
combining serum IGFBP-3 with biopsy T-stage and
biopsy Gleason score, it has been possible in our
study population to calculate a risk score with good
ability to predict significant GSU. These findings may
be useful in clinical management of PCa patients
particularly when AS or low dose brachytherapy are
considered. Since we showed the ability of risk score
to improve the discrimination between patients who
were upgraded and those who were not upgraded,
we encourage further carefully designed study on
large population in order to demonstrate the useful-
ness of IGFBP-3 as a routine marker for clinical use
in PCa patient management, considering also that
IGFBP-3 serum values were influenced by genetic
variations [58–60].
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